Clinical outcomes with 6 months dual antiplatelet therapy after implantation of Biolimus-A9 drug eluting coronary stents

Cockburn, James; Pareek, Nilesh; Poliačiková, Petra; Saraf, Smriti; Williams, Rupert; Dhillon, Gurpreet; Robinson, Derek; Hatrick, Robert; Blows, Lucy; Belder, Adam de; Hildick‐Smith, David

doi:10.1016/j.ijcard.2013.12.167

Cited by 6 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Post hoc analysis of the CREATE (Multi‐Center Registry of EXCEL Biodegradable Polymer Drug‐Eluting Stents) study also demonstrated sustained 3‐year clinical safety and efficacy of BP‐SES with 6 months of DAPT in a “real‐world” setting . Cockburn et al suggested that after the implantation of biodegradable polymer biolimus‐eluting coronary stents, 6 months of DAPT appears to be adequate, safe, and effective .…”

Section: Discussionmentioning

confidence: 98%

“…Previous meta‐analyses have reported that BP‐DES is superior to DP‐DES for reducing late or very late ST as well as target lesion revascularization (TLR) . Recently, some studies have investigated the optimal DAPT duration for BP‐DES and found that the effectiveness and safety profiles of 6‐month DAPT are similar to those of 12‐month DAPT after BP‐DES implantation . Therefore, current guidelines encourage a 3‐ to 6‐month DAPT regimen for patients with stable coronary artery disease who are receiving a new generation DES implantation .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Safety and efficacy of 6‐month versus 12‐month dual antiplatelet therapy in patients after implantation of multiple biodegradable polymer‐coated sirolimus‐eluting coronary stents: Insight from the I‐LOVE‐IT 2 trial

et al. 2017

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

Safety and efficacy of 6‐month versus 12‐month dual antiplatelet therapy in patients after implantation of multiple biodegradable polymer‐coated sirolimus‐eluting coronary stents: Insight from the I‐LOVE‐IT 2 trial

et al. 2017

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

“…Post hoc analysis of the CREATE (Multi-Center Registry of EXCEL Biodegradable Polymer Drug-Eluting Stents) study also demonstrated sustained 3-year clinical safety and efficacy of BP-SES with 6 months of DAPT in a "realworld" setting [5]. Cockburn et al suggested that after the implantation of biodegradable polymer biolimuseluting coronary stents, 6 months of DAPT appears to be adequate, safe, and effective [6].…”

Section: Discussionmentioning

confidence: 99%

“…Recently, some studies have investigated the optimal DAPT duration for BP-DES and found that the effectiveness and safety profiles of 6-month DAPT are similar to those of 12-month DAPT after BP-DES implantation [5,6]. Therefore, current guidelines encourage a 3-to 6-month DAPT regimen for patients with stable coronary artery disease who are receiving a new generation DES implantation [7,8].…”

Section: Introductionmentioning

confidence: 99%

GW28-e1117 Safety and efficacy of 6-month versus 12-month dual antiplatelet therapy on patients after implantation of multiple biodegradable polymer drug eluting coronary stents - a subgroup analysis from I-LOVE-IT 2 trial

Qi¹,

Li²,

Wang³

et al. 2017

Journal of the American College of Cardiology

View full text Add to dashboard Cite

Objective: This study sought to compare the clinical outcomes of 6-month versus 12-month dual antiplatelet therapy (DAPT) in patients receiving multiple biodegradable polymer-coated sirolimus-eluting stents (BP-SES) implants. Background: The clinical outcomes for patients who undergo multiple BP-SES implantation with different DAPT durations are uncertain. Methods: In the I-LOVE-IT 2 trial, 907 patients treated with multiple BP-SES (total stent number 2) were assigned to receive 6-month (n 5 440) or 12-month (n 5 467) DAPT. The primary endpoint was 12-month target lesion failure (TLF), which is a composite of cardiac death, target vessel myocardial infarction (MI) or clinically indicated target lesion revascularization. The major secondary endpoints were 12-month net adverse clinical events, a composite of all causes of death, MI, stroke, any revascularization and bleeding. Results: The number of stents per patient between the 6-month and 12-month DAPT group was similar (2.4 6 0.7 vs. 2.4 6 0.7, P 5 0.47). The incidence of 12-month TLF was comparable in the 6-month and 12-month DAPT groups (9.3% vs.7.5%, Log-rank P 5 0.33). However, landmark analysis showed that 12-month DAPT, compared to 6-month DAPT, was associated with a significantly lower risk of TLF (4.8% vs. 2.4%, Log-rank P 5 0.049) at a cost of a slightly increased risk of all bleeding events (0.5% vs. 1.7%, Log-rank P 5 0.07) between 6 and 12 months. Conclusions: In patients treated with multiple BP-SES, 6-and 12-month DAPT had similar impacts on 12-month clinical outcomes. Additionally, 12-month DAPT might reduce TLF between 6 and 12 months at the cost of a slightly increased risk of all bleeding events. V C 2017 Wiley Periodicals, Inc.

show abstract

“…The recent trial reported that a short duration (6 months) would be adequate, safe, and effective after implantation of BES. 27 That is because the second- and third-generation DESs, especially biodegradable BESs, are likely to present less concerns about ST that occurs as a result of inflammation during healing. 28 29 However, the optimal duration of dual antiplatelet therapy in patients with ACS, especially AMI, would be different than that in those of stable coronary disease.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness and Safety of Biolimus A9™-Eluting stEnt in Patients with AcUTe Coronary sYndrome; A Multicenter, Observational Study (BEAUTY Study)

et al. 2018

View full text Add to dashboard Cite

PurposeThis study sought to determine the 1-year clinical effectiveness and safety of a biodegradable, polymer-containing Biolimus A9™-eluting stent (BES) in Korean patients with acute coronary syndrome (ACS).Materials and MethodsA total of 1000 ACS patients with 1251 lesions who underwent implantation of BESs at 22 centers in Korea were enrolled between May 2011 and July 2013. We assessed major adverse cardiac events (MACE) defined as the composite of cardiac death, non-fatal myocardial infarction (MI), and clinical-driven target vessel revascularization at 12 months.ResultsPatient mean age was 62.6±11.4 years. 72.8% of the patients were male, 28.5% had diabetes, 32.8% had multi-vessel disease (MVD), and 47.9% presented with acute MI (AMI). The mean global registry of acute coronary events risk score of all patients was 103.0±27.6. The number of stents per patient was 1.3±0.6. The incidences of MACE and definite stent thrombosis at 12 months were 3.9% and 0.2%, respectively. On multivariate Cox-regression analysis, age ≥65 years was identified as an independent predictors of 1-year MACE (hazard ratio=2.474; 95% confidence interval=1.202−5.091). Subgroup analyses revealed no significant differences in the incidence of MACE between patients with and without diabetes (4.3% vs. 3.7%, p=0.667), between those who presented with and without AMI (4.4% vs. 3.4%, p=0.403), and between those with and without MVD (4.6% vs. 3.5%, p=0.387).ConclusionOur study demonstrated excellent 1-year clinical outcomes of BES implantation in patients at low-risk for ACS.

show abstract

Clinical outcomes with 6 months dual antiplatelet therapy after implantation of Biolimus-A9 drug eluting coronary stents

Cited by 6 publications

References 25 publications

Safety and efficacy of 6‐month versus 12‐month dual antiplatelet therapy in patients after implantation of multiple biodegradable polymer‐coated sirolimus‐eluting coronary stents: Insight from the I‐LOVE‐IT 2 trial

Safety and efficacy of 6‐month versus 12‐month dual antiplatelet therapy in patients after implantation of multiple biodegradable polymer‐coated sirolimus‐eluting coronary stents: Insight from the I‐LOVE‐IT 2 trial

GW28-e1117 Safety and efficacy of 6-month versus 12-month dual antiplatelet therapy on patients after implantation of multiple biodegradable polymer drug eluting coronary stents - a subgroup analysis from I-LOVE-IT 2 trial

Effectiveness and Safety of Biolimus A9™-Eluting stEnt in Patients with AcUTe Coronary sYndrome; A Multicenter, Observational Study (BEAUTY Study)

Contact Info

Product

Resources

About